Tessari Eben 4
4 · Kiniksa Pharmaceuticals International, plc · Filed Oct 1, 2025
Insider Transaction Report
Form 4
Tessari Eben
CHIEF STRATEGY OFFICER
Transactions
- Sale
Class A Ordinary Share
2025-09-29$38.33/sh−42,000$1,609,860→ 34,552 total - Exercise/Conversion
Share Option
2025-09-29−42,000→ 0 totalExercise: $17.92Exp: 2029-03-03→ Class A Ordinary Share (42,000 underlying) - Exercise/Conversion
Class A Ordinary Share
2025-09-29$17.92/sh+42,000$752,640→ 76,552 total
Footnotes (3)
- [F1]This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.
- [F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $37.92 and $38.85. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- [F3]The option is fully vested and exercisable.